Current indications for surgery in patients with lung cancer after neoadjuvant targeted therapy: a systematic review.

Abstract excerpt

Neoadjuvant targeted therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is emerging as a strategy to improve outcomes in resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC) with EGFR mutations. We conducted a systematic review of clinical trials and studies, following PRISMA guidelines, to evaluate the efficacy, safety, and surgical feasibility of neoadjuvant EGFR-TKI...

Topics

• Humans
• Neoadjuvant Therapy
• Lung Neoplasms
• Carcinoma, Non-Small-Cell Lung
• ErbB Receptors
• Protein Kinase Inhibitors
• Molecular Targeted Therapy
• Treatment Outcome
• Pathologic Complete Response
• Neoplasm Staging
• Mutation